Open access
Sep 2026
Cost-effectiveness of the hepatitis B birth-dose vaccine in South Africa: a mathematical modelling analysis.
The findings support implementation of a universal HepB-BD policy alongside South Africa's current hepatitis B viral transmission elimination efforts and were modelled to be the most cost-effective option at a willingness-to-pay threshold of 0·5 × per-capita gross domestic product (ZAR 57 281).
Christopher P. Seaman, Christopher R. Bailie, C. Spearman et al.
· Lancet Global Health · 1 citation